Let's start with the global RSV market. What is RSV? This is respiratory and

antitial virus. It's a common cold for most people, but for the elderly and the infants,

it can lead to hospitalization. So we have a market now developing it with the vaccinations,

and there's vaccinations and there's monoclonal antibodies. So they're both kind of competing for this market in those age groups, the older age groups and then the infants. And you can see here in this kind of overview of the market looking at the 2030 forecasts. It says considering both the modalities antibody and vaccine targeting all three key age groups, the global RSV vaccine and antibody market is expected

to be worth $2.61 billion in 2024 raising to US $13.59 billion by 2030.

Now this has been a market that's been historically plagued with some issues in the clinical

trials in trying to get these vaccines, especially in children.

So when I saw this headline from NBC Chicago, FDA approves Merck's RSV shot for infants

wrapping up competition with Sanofi and AstraZeneca.

This is for newborns and infants.

FDA authorized, authorizes use newborns during the, whether they're entering or during the first

RSV season of their life.

So this is a monoclonal antibody shot.

And let's look at the clinical trials for this.

So all drug companies have to go through clinical trials.gov.

They have to basically state their intentions and any updates on these trials, they have to

post this here.

And this is the final trial.

This was the Merck efficacy and safety of chalcerobamab.

That's their RSV monoclonal antibody shot.

And this is an infant's.

So just to start out here, twice as many people is it's a caveat

...